Key Takeaways Bristol Myers' Opdivo growth is fueled by new launches, label expansions, and solid global uptake.EC approved subcutaneous Opdivo and Opdivo Qvantig, boosting momentum across multiple tumor types.BMY trades at 7.60x forward earnings, below industry peers, as EPS estimates trend upward for 2025-2026.Bristol Myers ((BMY) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, Opdivo Qvantig, and Yervoy, among others.Opdivo is a key drug in BMY’s Growth Portfolio that ...

Target recently launched an Enterprise Acceleration Office, led by chief operating officer Michael Fiddelke. It hopes this will help boost productivity and efficiency across the business, notably by implementing tech-based changes. Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like these, it's worthwhile to remember that stock-market swings, even full-blown crashes, are par for the course; they don't change the fact that ove ...